PHARMING GROUP NV - ADR
PHARNASDAQTrading Snapshot
- Day Range
- $9.92 โ $10.06
- 52-Week Range
- $0.83 โ $1.82
- Volume
- $5.83B
- Avg Volume
- $5.25B
- Shares Outstanding
- 707.8M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $376M
- Last Q Revenue
- $90M
- P/E Ratio
- 80.3
- P/S Ratio
- 2.0x
- EPS (TTM)
- $0.02
- Dividend Yield
- โ
- Dilution (1yr)
- +11.4%
Why Investors Own PHAR
- โHigh-growth profile โ revenue up +57.2% YoY with expanding US Equity exposure.
- โHealthy economics โ 56% gross margin and 9% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PHARMING GROUP NV - ADR
PHAR
StockOtter ยท stockotter.spaceAbout PHARMING GROUP NV - ADR
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Price Target
โLatest News & Updates
Pharming announces CEO transition
Leiden, the Netherlands, September 29, 2026 : Pharmingย (Euronext Amsterdam: PHARM/Nasdaq: PHAR),ย a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenjaยฎ to treat children with APDS
If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results fro
MAC Alpha Capital Management LP Makes New $29.84 Million Investment in Pharming Group N.V. Sponsored ADR $PHAR
MAC Alpha Capital Management LP acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exc
FDA approves Pharming's Joenjaยฎ as first treatment for children with APDS in the U.S.
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kฮด) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are expected to be availa
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3